Biological therapy update in colorectal cancer (Q36764932)

16 August 2017

1 reference

title

Biological therapy update in colorectal cancer (English)

1 reference

16 August 2017

1 reference

Steven M Sorscher

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 April 2007

1 reference

Expert Opinion on Biological Therapy

16 August 2017

1 reference

inferred from page(s)

published in

1 reference

16 August 2017

1 reference

16 August 2017

1 reference

16 August 2017

page(s)

509-519

1 reference

Tumorigenesis and the angiogenic switch

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.509

Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.509

VEGF and the quest for tumour angiogenesis factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.509

Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.509

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.509

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.509

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.509

Anti-VEGF antibody bevacizumab (Avastin) with 5FU/LV as third line treatment for colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.509

Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.509

Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.509

The future development of bevacizumab in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.509

Why the epidermal growth factor receptor? The rationale for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.509

Epithelial growth factor receptor interacting agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.509

Epidermal growth factor-related peptides and their receptors in human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.509

The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.509

Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.509

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.509

Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.509

In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.509

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.509

Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.509

Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lun

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.509

Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.509

Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.509

A phase III randomized, open-label, controlled trial of chemotherapy and bevacizumab with or without panitumumab in the first-line treatment of patients with metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.509

Molecular determinants of cetuximab efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.509

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.509

Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.509

Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.509

21 January 2018

Identifiers

DOI

10.1517/14712598.7.4.509

1 reference

16 August 2017

1 reference